川宁生物：下游集采的改变，对公司下游的产品会有一定的影响，但对公司中间体的价格影响较小

Group 1 - The change in drug procurement strategy no longer focuses solely on low prices, which may impact the company's downstream products [2] - The company indicated that the impact on the prices of intermediates would be minimal [2]